1CM Past Earnings Performance
Past criteria checks 3/6
1CM has been growing earnings at an average annual rate of 63.7%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 81.3% per year. 1CM's return on equity is 2.2%, and it has net margins of 1.1%.
Key information
63.7%
Earnings growth rate
66.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 81.3% |
| Return on equity | 2.2% |
| Net Margin | 1.1% |
| Last Earnings Update | 31 Aug 2024 |
Recent past performance updates
Recent updates
Even With A 135% Surge, Cautious Investors Are Not Rewarding 1CM Inc.'s (CSE:EPIC) Performance Completely
Nov 27
1CM Inc. (CSE:EPIC) Might Not Be As Mispriced As It Looks After Plunging 30%
Sep 291CM Inc. (CSE:EPIC) Stock's 32% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 15Not Many Are Piling Into 1CM Inc. (CSE:EPIC) Stock Yet As It Plummets 32%
Jun 16Why We're Not Concerned Yet About 1CM Inc.'s (CSE:EPIC) 33% Share Price Plunge
Apr 27What You Can Learn From 1CM Inc.'s (CSE:EPIC) P/S
Feb 07Investors Appear Satisfied With 1CM Inc.'s (CSE:EPIC) Prospects
Jun 27Revenue & Expenses Breakdown
How 1CM makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 57 | 1 | 8 | 0 |
| 31 May 24 | 52 | -1 | 8 | 0 |
| 29 Feb 24 | 46 | -1 | 7 | 0 |
| 30 Nov 23 | 40 | -2 | 7 | 0 |
| 31 Aug 23 | 35 | -1 | 6 | 0 |
| 31 May 23 | 24 | -2 | 7 | 0 |
| 28 Feb 23 | 15 | -3 | 6 | 0 |
| 30 Nov 22 | 8 | -3 | 4 | 0 |
| 31 Aug 22 | 1 | -5 | 3 | 0 |
| 31 May 22 | 1 | -5 | 4 | 0 |
| 28 Feb 22 | 1 | -5 | 5 | 0 |
| 30 Nov 21 | 1 | -5 | 4 | 0 |
| 31 Aug 21 | 0 | -5 | 4 | 0 |
| 31 May 21 | 0 | -4 | 2 | 0 |
| 28 Feb 21 | 0 | -3 | 1 | 0 |
| 30 Nov 20 | 0 | -3 | 1 | 0 |
| 31 Aug 20 | 0 | -3 | 1 | 0 |
| 31 May 20 | 0 | -28 | 1 | 0 |
| 29 Feb 20 | 0 | -28 | 1 | 0 |
| 30 Nov 19 | 0 | -28 | 1 | 0 |
| 31 Aug 19 | 0 | -29 | 1 | 0 |
| 31 May 19 | 0 | -7 | 5 | 0 |
| 28 Feb 19 | 0 | -8 | 6 | 0 |
| 30 Nov 18 | 0 | -7 | 6 | 0 |
| 31 Aug 18 | 0 | -6 | 6 | 0 |
| 31 May 18 | 0 | -2 | 2 | 0 |
| 28 Feb 18 | 0 | 0 | 0 | 0 |
| 30 Nov 17 | 0 | 0 | 0 | 0 |
| 31 Aug 17 | 0 | 0 | 0 | 0 |
| 31 May 17 | 0 | 0 | 0 | 0 |
| 28 Feb 17 | 0 | 0 | 0 | 0 |
| 30 Nov 16 | 0 | 0 | 0 | 0 |
| 31 Aug 16 | 0 | 0 | 0 | 0 |
| 31 May 16 | 0 | -1 | 0 | 0 |
| 29 Feb 16 | 0 | -1 | 0 | 0 |
| 30 Nov 15 | 0 | -1 | 0 | 0 |
| 31 Aug 15 | 0 | -1 | 0 | 0 |
| 31 May 15 | 0 | -1 | 0 | 0 |
| 28 Feb 15 | 0 | 0 | 0 | 0 |
| 30 Nov 14 | 0 | -2 | 0 | 0 |
Quality Earnings: EPIC has high quality earnings.
Growing Profit Margin: EPIC became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EPIC has become profitable over the past 5 years, growing earnings by 63.7% per year.
Accelerating Growth: EPIC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: EPIC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: EPIC's Return on Equity (2.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 13:58 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
1CM Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|